Scribe Therapeutics Inc. Common Stock - Asset Resilience Ratio
Scribe Therapeutics Inc. Common Stock (SCTX) has an Asset Resilience Ratio of 12.81% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SCTX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Scribe Therapeutics Inc. Common Stock's Asset Resilience Ratio has changed over time. See Scribe Therapeutics Inc. Common Stock free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Scribe Therapeutics Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SCTX current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.42 Million | 12.81% |
| Total Liquid Assets | $7.42 Million | 12.81% |
Asset Resilience Insights
- Moderate Liquidity: Scribe Therapeutics Inc. Common Stock has 12.81% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Scribe Therapeutics Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Scribe Therapeutics Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.40% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
Annual Asset Resilience Ratio for Scribe Therapeutics Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Scribe Therapeutics Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.74% | $45.17 Million | $78.22 Million | -14.59pp |
| 2024-12-31 | 72.34% | $92.57 Million | $127.97 Million | -- |
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200… Read more